Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of ...
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...
A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models ...
Since being diagnosed with depression in 1995, Leonie Schneider has been prescribed antidepressants for over 24 years. “To be ...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from ...
Howard Steinberg was a successful, married businessman until it all fell apart. Experimenting with magic mushrooms helped him ...
New research suggests the broader social climate may shape psychedelic experiences and their lasting psychological effects.
Investor's Business Daily on MSN
Eli Lilly trips into red-hot psychedelics space with a big takeover
Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results